Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Ex-drug executive Shkreli pleads not guilty to latest charge

Published 06/06/2016, 18:54
© Reuters. Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives at a U.S. Federal Court in New York
TVTX
-

By David Ingram

NEW YORK (Reuters) - Former pharmaceutical executive Martin Shkreli, a lightning rod for outrage over soaring U.S. prescription drug prices, pleaded not guilty on Monday to an additional criminal charge that federal prosecutors filed against him last week.

Shkreli, 33, was indicted in December on seven criminal counts, including securities fraud. Prosecutors on Friday added an eighth charge, saying Shkreli tried to conceal from investors his control over shares in Retrophin Inc (O:RTRX).

Evan Greebel, former outside counsel to Retrophin, also pleaded not guilty to the charge at a court hearing in the New York City borough of Brooklyn. Greebel faces two counts in all.

Shkreli last year sparked outrage among patients, medical societies and U.S. lawmakers after another company he ran, Turing Pharmaceuticals, raised the price of Daraprim by more than 5,000 percent to $750 (£519) a pill.

In December, U.S. authorities arrested him on fraud charges unrelated to the pricing of Daraprim, saying he ran his investment funds and companies almost like a Ponzi scheme.

© Reuters. Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, arrives at a U.S. Federal Court in New York

U.S. District Judge Kiyo Matsumoto declined during Monday's hearing to set a trial date for Shkreli and Greebel but said she was considering an early 2017 time frame.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.